Chardan Capital restated their buy rating on shares of CervoMed (NASDAQ:CRVO – Free Report) in a report published on Thursday,Benzinga reports. The brokerage currently has a $55.00 price objective on the stock. Other equities research analysts also recently issued research reports about the company. Morgan Stanley assumed coverage on CervoMed in a report on Friday, […]

Chardan Capital restated their buy rating on shares of Passage Bio (NASDAQ:PASG – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $7.00 target price on the stock. PASG has been the subject of several other research reports. Canaccord Genuity Group reissued a “buy” rating and issued a […]

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Chardan Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $62.00 price target on the biotechnology company’s stock. Chardan Capital’s price target would suggest a potential upside of 267.73% from the company’s […]

Ocugen (NASDAQ:OCGN – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a report issued on Friday,Benzinga reports. They currently have a $6.00 target price on the stock. Chardan Capital’s price objective indicates a potential upside of 460.75% from the company’s previous close. Several other research firms have […]